Second medical use
Surprise success for Bayer blockbuster Xarelto at EPO
The EPO Boards of Appeal have reinstated the dosing patent for Bayer's thrombosis blockbuster drug, Xarelto. In the first instance, the patent was rev
...
28 October 2021 by Christina Schulze